Literature DB >> 26054944

Estimation of life expectancy and the expected years of life lost among heroin users in the era of opioid substitution treatment (OST) in Taiwan.

Kun-Chia Chang1, Tsung-Hsueh Lu2, Kuan-Ying Lee3, Jing-Shiang Hwang4, Ching-Ming Cheng5, Jung-Der Wang6.   

Abstract

BACKGROUND: Opioid substitution treatment (OST) has been implemented in Taiwan since 2006. We estimated the life expectancy (LE) and expected years of life lost (EYLL) in a cohort of heroin users stratified by OST for comparison.
METHODS: A total of 1283 heroin users recruited from 2006 to 2008 were linked to the National Mortality Registry until the end of 2011. Among them, 983 received OST, while 300 did not. Kaplan-Meier estimation for survival was performed, and it was extrapolated to 50 years to obtain the LE using a semi-parametric method. We further estimated the EYLL for both cohorts by subtracting their life expectancies from the age- and sex-matched referents of the general population. Cause-specific standardized mortality ratios (SMRs) were calculated and compared with the national cohort to validate the representativeness of this sample.
RESULTS: After extrapolation to 50 years of survival, the estimated average LE and EYLL were 27.4 and 10.6 for OST subjects, respectively, while those of the non-OST were 20.2 and 18.4 years. The all-cause mortality rates (per 1000 person-years) in the observational period for the OST and non-OST group were 15.5 and 23.9, respectively, representing a 7.5- and 10.2-fold SMR compared to the general population, indicating a high representativeness for our sample. But SMR of suicide mortality elevated 16.2 and 3.1 folds in OST and non-OST group, respectively.
CONCLUSIONS: OST saves 7.8 EYLL more than non-OST after accounting for lead time bias. Effective suicide prevention programs could enhance its life-saving effect, especially among those co-morbid with depressive disorders.
Copyright © 2015 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.

Entities:  

Keywords:  Heroin; Life expectancy; Mortality; Opioid substitution treatment; Suicide

Mesh:

Year:  2015        PMID: 26054944     DOI: 10.1016/j.drugalcdep.2015.05.033

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  6 in total

1.  Causes of death and expected years of life lost among treated opioid-dependent individuals in the United States and Taiwan.

Authors:  Kun-Chia Chang; Jung-Der Wang; Andrew Saxon; Abigail G Matthews; George Woody; Yih-Ing Hser
Journal:  Int J Drug Policy       Date:  2017-02-01

Review 2.  The Role of Physical Activity in Opioid Substitution Therapy: A Systematic Review of Interventional and Observational Studies.

Authors:  Silvia Eiken Alpers; Einar Furulund; Ståle Pallesen; Asgeir Mamen; Sindre M Dyrstad; Lars Thore Fadnes
Journal:  Subst Abuse       Date:  2022-07-12

Review 3.  Intracellular Signaling Cascades in Bipolar Disorder.

Authors:  Gregory H Jones; Carola Rong; Aisha S Shariq; Abhinav Mishra; Rodrigo Machado-Vieira
Journal:  Curr Top Behav Neurosci       Date:  2021

4.  Implementation of methadone therapy for opioid use disorder in Russia - a modeled cost-effectiveness analysis.

Authors:  Bulat Idrisov; Sean M Murphy; Tyler Morrill; Mayada Saadoun; Karsten Lunze; Donald Shepard
Journal:  Subst Abuse Treat Prev Policy       Date:  2017-01-20

5.  Cost-effectiveness of hemodialysis and peritoneal dialysis: A national cohort study with 14 years follow-up and matched for comorbidities and propensity score.

Authors:  Yu-Tzu Chang; Jing-Shiang Hwang; Shih-Yuan Hung; Min-Sung Tsai; Jia-Ling Wu; Junne-Ming Sung; Jung-Der Wang
Journal:  Sci Rep       Date:  2016-07-27       Impact factor: 4.379

6.  A retrospective cohort study evaluating correlates of deep tissue infections among patients enrolled in opioid agonist treatment using administrative data in Ontario, Canada.

Authors:  Kristen A Morin; Chad R Prevost; Joseph K Eibl; Michael T Franklyn; Alexander R Moise; David C Marsh
Journal:  PLoS One       Date:  2020-04-24       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.